Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort Study.

Clinical and translational gastroenterology·2026
Same author

IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.

Alimentary pharmacology & therapeutics·2025
Same author

Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.

United European gastroenterology journal·2024
Same author

Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.

Journal of the Canadian Association of Gastroenterology·2024
Same author

Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.

Crohn's & colitis 360·2024
Same author

HLADQA1∗05G>A Genetic Screening Promotes the Safe Delivery of Combination Therapy in Inflammatory Bowel Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023

Related Experiment Video

Updated: Jul 2, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Microscopic colitis: an approach to treatment.

Nilesh Chande1

  • 1Division of Gastroenterology, The University of Western Ontario, London Health Sciences Centre-South Street Hospital, London, Ontario. nchande2@uwo.ca

Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|August 15, 2008
PubMed
Summary

Microscopic colitis, including collagenous and lymphocytic types, causes chronic watery diarrhea in adults. Treatment involves medications and sometimes surgery, aiming for optimal response with minimal side effects.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Related Experiment Videos

Last Updated: Jul 2, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pathology

Background:

  • Microscopic colitis, encompassing collagenous colitis and lymphocytic colitis, is a condition characterized by chronic watery diarrhea.
  • It predominantly affects middle-aged and elderly individuals.
  • Associations with celiac disease and specific medications are noted.

Purpose of the Study:

  • To provide an evidence-based and practical approach to managing microscopic colitis.
  • To optimize treatment response in patients with microscopic colitis.
  • To minimize potential adverse events associated with microscopic colitis treatments.

Main Methods:

  • Review of current medical literature on microscopic colitis treatment.
  • Analysis of treatment options including antidiarrheal agents, mesalamine, corticosteroids, and immunosuppressants.
  • Consideration of surgical interventions for refractory cases.

Main Results:

  • Various pharmacological agents are employed for medical management.
  • Surgery is a rare option for patients with treatment-resistant disease.
  • An evidence-based approach is crucial for effective management.

Conclusions:

  • Effective management of microscopic colitis requires a tailored, evidence-based strategy.
  • Balancing treatment efficacy with the minimization of adverse events is paramount.
  • Further research may refine treatment protocols for microscopic colitis.